Damora Therapeutics gets buy rating from Guggenheim with $60 target
DMRA•Guggenheim assumed coverage of Damora Therapeutics with a buy rating and a $60 target price.
Related News
Republic Services: Citigroup raises target price to $281 from $259
RSG•
Cognition Therapeutics to host third-quarter financial results call
CGTX•
Everest Group target price raised to $450 from $400
EG•
West Fraser Timber Co. Ltd.: BMO cuts target price to $87 from $90
WFG•
Apeiron increases Enhanced Group stake with about 900,000 additional shares
ENHA•